Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden
Identifieur interne : 001289 ( Main/Exploration ); précédent : 001288; suivant : 001290Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden
Auteurs : Alastair J. Hutchison [Royaume-Uni] ; Maurice Laville [France]Source :
- Nephrology Dialysis Transplantation [ 0931-0509 ] ; 2008-11.
Abstract
Background. Despite recognized risks associated with hyperphosphataemia in patients with chronic kidney disease (CKD) Stage 5 on dialysis, the achievement of target levels of serum phosphate is poor. It is likely that this is partly due to poor adherence by patients to their phosphate-binder treatment regimens, which often comprise large daily tablet burdens. Methods. In this multicentre, open-label trial, patients on a stable dialysis regimen were screened while receiving phosphate-binder therapy, then entered into a washout phase. Patients with serum phosphate > 1.78 mmolL after washout entered into the main 12-week treatment phase (N 367), during which they were treated to target Kidney Disease Outcomes Quality Initiative (KDOQI): 1.131.78 mmolL; 3.55.5 mgdL) with lanthanum carbonate monotherapy. Efficacy variables included serum phosphate levels and the percentage of patients with serum phosphate control. Safety and tolerability assessments were also conducted. Results. Mean serum phosphate levels were significantly reduced following 12 weeks of lanthanum carbonate monotherapy versus previous phosphate-binder therapy. The mean number of phosphate-binder tablets being taken per day at screening was 7.6, but during treatment with lanthanum carbonate, most patients were taking doses of up to 3000 mgday, achievable with 3 1000 mg tablets per day (maximum of 6). Conclusion. These findings suggest that lanthanum carbonate monotherapy offers effective control of serum phosphate and, due to a low tablet burden, may help to simplify the management of hyperphosphataemia in patients with CKD Stage 5.
Url:
DOI: 10.1093/ndt/gfn310
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000A47
- to stream Istex, to step Curation: 000A46
- to stream Istex, to step Checkpoint: 000D75
- to stream Main, to step Merge: 001292
- to stream Main, to step Curation: 001289
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden</title><author><name sortKey="Hutchison, Alastair J" sort="Hutchison, Alastair J" uniqKey="Hutchison A" first="Alastair J." last="Hutchison">Alastair J. Hutchison</name></author><author><name sortKey="Laville, Maurice" sort="Laville, Maurice" uniqKey="Laville M" first="Maurice" last="Laville">Maurice Laville</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DA4A299A8C9C1FD12012F47F114907356319FD10</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1093/ndt/gfn310</idno><idno type="url">https://api.istex.fr/document/DA4A299A8C9C1FD12012F47F114907356319FD10/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000A47</idno><idno type="wicri:Area/Istex/Curation">000A46</idno><idno type="wicri:Area/Istex/Checkpoint">000D75</idno><idno type="wicri:doubleKey">0931-0509:2008:Hutchison A:switching:to:lanthanum</idno><idno type="wicri:Area/Main/Merge">001292</idno><idno type="wicri:Area/Main/Curation">001289</idno><idno type="wicri:Area/Main/Exploration">001289</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden</title><author><name sortKey="Hutchison, Alastair J" sort="Hutchison, Alastair J" uniqKey="Hutchison A" first="Alastair J." last="Hutchison">Alastair J. Hutchison</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Manchester Royal Infirmary, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Laville, Maurice" sort="Laville, Maurice" uniqKey="Laville M" first="Maurice" last="Laville">Maurice Laville</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service de Nphrologie, Universit Claude-Bernard Lyon 1, Hpital Edouard-Herriot, Lyon</wicri:regionArea><placeName><settlement type="city">Lyon</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Nephrology Dialysis Transplantation</title><title level="j" type="abbrev">Nephrol Dial Transplant</title><idno type="ISSN">0931-0509</idno><idno type="eISSN">1460-2385</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2008-11">2008-11</date><biblScope unit="volume">23</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="3677">3677</biblScope><biblScope unit="page" to="3684">3684</biblScope></imprint><idno type="ISSN">0931-0509</idno></series><idno type="istex">DA4A299A8C9C1FD12012F47F114907356319FD10</idno><idno type="DOI">10.1093/ndt/gfn310</idno><idno type="ArticleID">gfn310</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0931-0509</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Background. Despite recognized risks associated with hyperphosphataemia in patients with chronic kidney disease (CKD) Stage 5 on dialysis, the achievement of target levels of serum phosphate is poor. It is likely that this is partly due to poor adherence by patients to their phosphate-binder treatment regimens, which often comprise large daily tablet burdens. Methods. In this multicentre, open-label trial, patients on a stable dialysis regimen were screened while receiving phosphate-binder therapy, then entered into a washout phase. Patients with serum phosphate > 1.78 mmolL after washout entered into the main 12-week treatment phase (N 367), during which they were treated to target Kidney Disease Outcomes Quality Initiative (KDOQI): 1.131.78 mmolL; 3.55.5 mgdL) with lanthanum carbonate monotherapy. Efficacy variables included serum phosphate levels and the percentage of patients with serum phosphate control. Safety and tolerability assessments were also conducted. Results. Mean serum phosphate levels were significantly reduced following 12 weeks of lanthanum carbonate monotherapy versus previous phosphate-binder therapy. The mean number of phosphate-binder tablets being taken per day at screening was 7.6, but during treatment with lanthanum carbonate, most patients were taking doses of up to 3000 mgday, achievable with 3 1000 mg tablets per day (maximum of 6). Conclusion. These findings suggest that lanthanum carbonate monotherapy offers effective control of serum phosphate and, due to a low tablet burden, may help to simplify the management of hyperphosphataemia in patients with CKD Stage 5.</div></front></TEI><affiliations><list><country><li>France</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Manchester</li></region><settlement><li>Lyon</li><li>Manchester</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Hutchison, Alastair J" sort="Hutchison, Alastair J" uniqKey="Hutchison A" first="Alastair J." last="Hutchison">Alastair J. Hutchison</name></region></country><country name="France"><noRegion><name sortKey="Laville, Maurice" sort="Laville, Maurice" uniqKey="Laville M" first="Maurice" last="Laville">Maurice Laville</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001289 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001289 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Belgique
|area= OpenAccessBelV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:DA4A299A8C9C1FD12012F47F114907356319FD10
|texte= Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden
}}
| This area was generated with Dilib version V0.6.25. |  |